QC
CLDX icon

Quadrature Capital’s Celldex Therapeutics CLDX Stock Holding History

Quadrature Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$627K Sell
16,846
-7,594
-31% -$245K 0.01% 932
2026
Q1 		$775K Buy
+24,440
New +$666K 0.01% 649
2025
Q3 		– Sell
-11,656
Closed -$238K – 1098
2025
Q2 		$238K Buy
+11,656
New +$227K ﹤0.01% 765

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's CLDX Position: Q2 2026 in Review

Quadrature Capital reduced its Celldex Therapeutics (CLDX) stake by 31% in Q2 2026, selling an estimated $245K and leaving 16,846 shares worth $627K. The position accounts for 0.01% of the portfolio, ranked #932.

Quadrature Capital first reported a position in CLDX in Q2 2025 and has held it in 3 quarters since. The position peaked at $775K in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Quadrature Capital held 16,846 shares of Celldex Therapeutics worth $627K as of Q2 2026.
  • Quadrature Capital sold 7,594 Celldex Therapeutics shares in Q2 2026, an estimated $245K.
  • Celldex Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #932 holding.
  • Quadrature Capital first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Celldex Therapeutics position peaked at $775K in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.